Our perspectives
in one place
Topic
Selected filters
Clear
News
See allInnovative pharmaceutical industry welcomes B20 recognition of healthcare innovation as a driver of economic growth
12 November 2026, Geneva – The innovative pharmaceutical industry welcomes the Business20 (B20) Leaders’ Statement and its recognition of long-term investment in research and development (R&D) and healthcare innovation as key priorities for continued economic growth and prosperity. The B20 USA Summit concluded in Washington with global business and policy leaders united around accelerating growth...
Read moreBiopharmaceutical CEO Roundtable meets in New York
05 November 2026 – The Biopharmaceutical CEO Roundtable (BCR), bringing together CEOs from leading global biopharmaceutical companies, met in New York on 3–4 November to discuss the changing global policy environment and priorities for strengthening innovation, access, and the long-term competitiveness of the sector.
Read moreWIPO’s 38th Standing Committee on Patents: Technology transfer
On 5 November 2026, IFPMA delivered a statement on technology transfer at WIPO’s 38th Standing Committee on Patents. IFPMA notes the study in document SCP/38/9 on collaboration between industry and academia. We welcome the study’s recognition that robust intellectual property frameworks, capable partners, and appropriate financing help turn research into practical applications. Furthermore, we welcome...
Read moreWIPO’s 38th Standing Committee on Patents: Patents and health
On 4 November 2026, IFPMA delivered a statement on patents and health at WIPO’s 38th Standing Committee on Patents. A robust, stable, and predictable intellectual property system supports research and development, investment, and voluntary partnerships needed to translate scientific discoveries into innovative medicines and vaccines. As users of the patent system, including the Patent Cooperation...
Read moreStatement delivered at the opening plenary of the WHO Fair Pricing Forum 2026
On 3 November 2026, IFPMA delivered a statement at the opening plenary of the WHO Fair Pricing Forum.
Read moreStatement on PABS Instrument at the ninth meeting of the Intergovernmental Working Group (IGWG 9) on the WHO Pandemic Agreement
On 2 November 2026, IFPMA delivered a statement at the ninth meeting of the Intergovernmental Working Group (IGWG 9) on the WHO Pandemic Agreement.
Read morePublications
See allThe use of artificial intelligence in regulatory activities – key areas and considerations
Scientific innovation is transforming the way medicines are discovered, developed, and evaluated, creating new opportunities to generate and analyze increasingly complex data and evidence. Regulatory science and regulatory systems need to evolve alongside these advances to ensure that scientific innovation can be effectively translated into innovative medicines for patients. Against this backdrop, artificial intelligence offers...
Read more
Healthy planet, healthy people: The innovative pharmaceutical industry’s contribution to the Kunming-Montreal Global Biodiversity Framework
Through company-level initiatives and decades of pre-competitive collaboration, IFPMA member companies are working to reduce environmental impact and contribute positively to a healthy and biodiverse planet.
Read more
International data flows: Enabling data-driven, patient-centric innovative pharmaceutical research and development (R&D)
To fulfill the potential of data and new technologies in supporting the shared objective of improving patient lives and population health, it is vital that well-designed systems are put in place.
Read more
Expert insights
See all
The value of every 1% increase in influenza vaccination coverage
Read more
Business Strategy: Re-Centering Ethics as Pharma’s Competitive Advantage
Read more
Pharmaceutical innovation: A strategic investment in health and growth
Read moreResources
See allThe value of every 1% increase in influenza vaccination coverage
This IFPMA infographic shows how just a 1% increase in seasonal influenza vaccination coverage can deliver substantial health and economic benefits.
Read more
Adult immunization for healthy workforces and healthy economies in an aging world
IFPMA and the Global Coalition on Ageing (GCOA) outline why vaccination is essential to building healthier workforces and stronger economies in an aging world.
Read more
Streamlining samples management to strengthen health outcomes in Africa
Ensuring the quality, safety, and efficacy of pharmaceutical products is a cornerstone of public health. To meet these high standards, innovative multinational pharmaceutical companies perform rigorous batch release testing for every product, following internationally recognized protocols and approved specifications. However, countries may require additional in-country testing by their National Regulatory Authorities (NRAs) or National Control...
Read more